Publication:
Prognostic factors and outcomes for osteosarcoma: An international collaboration

dc.contributor.authorsPakos, Emilios E.; Nearchou, Andreas D.; Grimer, Robert J.; Koumoullis, Haris D.; Abudu, Adesegun; Bramer, Jos A. M.; Jeys, Lee M.; Franchi, Alessandro; Scoccianti, Guido; Campanacci, Domenico; Capanna, Rodolfio; Aparicio, Jorge; Tabone, Marie-Dominique; Holzer, Gerold; Abdolvahab, Fashid; Funovics, Philipp; Dominkus, Martin; Ilhan, Inci; Berrak, Su G.; Patino-Garcia, Ana; Sierrasesumaga, Luis; San-Julian, Mikel; Garraus, Moira; Petrili, Antonio Sergio; Garcia Filho, Reynaldo Jesus; Pacheco Donato Macedo, Carla Renata; de Seixas Alves, Maria Teresa; Seiwerth, Sven; Nagarajan, Rajaram; Cripe, Timothy P.; Ioannidis, John P. A.
dc.date.accessioned2022-03-12T17:47:04Z
dc.date.accessioned2026-01-11T15:12:15Z
dc.date.available2022-03-12T17:47:04Z
dc.date.issued2009
dc.description.abstractWe aimed to evaluate the prognostic significance of traditional clinical predictors in osteosarcoma through an international collaboration of 10 teams of investigators (2680 patients) who participated. In multivariate models the mortality risk increased with older age, presence of metastatic disease at diagnosis, development of local recurrence when the patient was first seen, use of amputation instead of limb salvage/wide resection, employment of unusual treatments, use of chemotherapeutic regimens other than anthracycline and platinum and use of methotrexate. it was also influenced by the site of the tumour. The risk of metastasis increased when metastatic disease was present at the time the patient was first seen and also increased with use of amputation or unusual treatment combinations or chemotherapy regimens not including anthracycline and platinum. Local recurrence risk was higher in older patients, in those who had local recurrence when first seen and when no anthracycline and platinum were used in chemotherapy. Results were similar when limited to patients seen after 1990 and treated with surgery plus combination chemotherapy. This large-scale international collaboration identifies strong predictors of major clinical outcomes in osteosarcoma. (C) 2009 Published by Elsevier Ltd.
dc.identifier.doi10.1016/j.ejca.2009.03.005
dc.identifier.eissn1879-0852
dc.identifier.issn0959-8049
dc.identifier.pubmed19349163
dc.identifier.urihttps://hdl.handle.net/11424/229658
dc.identifier.wosWOS:000270645700026
dc.language.isoeng
dc.publisherELSEVIER SCI LTD
dc.relation.ispartofEUROPEAN JOURNAL OF CANCER
dc.rightsinfo:eu-repo/semantics/closedAccess
dc.subjectOsteosarcoma
dc.subjectClinical predictors
dc.subjectPrognosis
dc.subjectSurvival
dc.subjectMetastasis
dc.subjectInternational collaboration
dc.subjectHIGH-DOSE METHOTREXATE
dc.subjectNONMETASTATIC OSTEOSARCOMA
dc.subjectADJUVANT CHEMOTHERAPY
dc.subjectMURAMYL TRIPEPTIDE
dc.subjectOSTEOGENIC-SARCOMA
dc.subjectRANDOMIZED-TRIAL
dc.subjectONCOLOGY-GROUP
dc.subjectLIMB-SALVAGE
dc.subjectSURVIVAL
dc.subjectINTERGROUP
dc.titlePrognostic factors and outcomes for osteosarcoma: An international collaboration
dc.typearticle
dspace.entity.typePublication
oaire.citation.endPage2375
oaire.citation.issue13
oaire.citation.startPage2367
oaire.citation.titleEUROPEAN JOURNAL OF CANCER
oaire.citation.volume45

Files